tiprankstipranks
Merck & Company (MRK)
NYSE:MRK

Merck & Company (MRK) Stock Price & Analysis

11,575 Followers

MRK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$97.22 - $134.63
Previous Close$127.76
Volume7.02M
Average Volume (3M)8.36M
Market Cap
$326.66B
Enterprise Value$355.32B
Total Cash (Recent Filing)$5.62B
Total Debt (Recent Filing)$34.22B
Price to Earnings (P/E)143.6
Beta0.14
Jul 30, 2024
Dividend Yield2.36%
Share Statistics
EPS (TTM)0.90
Shares Outstanding2,532,806,307
10 Day Avg. Volume8,283,382
30 Day Avg. Volume8,357,944
Standard Deviation0.06
R-Squared0.12
Alpha0.00807
Financial Highlights & Ratios
Price to Book (P/B)205.52
Price to Sales (P/S)5.51
Price to Cash Flow (P/CF)26.80
P/FCF Ratio33.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.79
Enterprise Value/Gross Profit8.08
Enterprise Value/Ebitda45.25
Forecast
Price Target Upside15.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say
Market Share And CompetitivenessCapvaxive’s ~85% disease coverage will be compelling to purchasers and prescribers.
Strategic Growth And PipelineMerck's strong pipeline of new drugs is expected to drive future growth.
Vaccine Approval And Market PotentialFDA approved Merck’s 21-valent pneumococcal conjugate vaccine (PCV) Capvaxive customized for adults based on outcomes from the Ph 3 STRIDE-03, STRIDE-5, and STRIDE-6 studies.
Bears Say
Patent ExpiryThe key risk to earnings is Keytruda’s patent expiry.
Product Launch DelaysThe trial for ivonescimab was only conducted in China and will require another global study for broader approval, estimated to take around 3 years.
Regulatory ChallengesThe FDA issued a Complete Response Letter (CRL) for MRK/Daiichi Sankyo's patritumab deruxtecan due to findings pertaining to an inspection of a third-party manufacturing facility.
---

Financials

Annual

Ownership Overview

0.16%22.29%19.49%58.06%
19.49% Other Institutional Investors
58.06% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

MRK FAQ

What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $97.22 and its highest was $134.63 in the past 12 months.
    What is Merck & Company’s market cap?
    Currently, no data Available
    When is Merck & Company’s upcoming earnings report date?
    Merck & Company’s upcoming earnings report date is Jul 30, 2024 which is in 17 days.
      How were Merck & Company’s earnings last quarter?
      Merck & Company released its earnings results on Apr 25, 2024. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.886 by $0.184.
        Is Merck & Company overvalued?
        According to Wall Street analysts Merck & Company’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Merck & Company pay dividends?
          Merck & Company pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 2.36%. See more information on Merck & Company dividends here
            What is Merck & Company’s EPS estimate?
            Merck & Company’s EPS estimate is $2.15.
              How many shares outstanding does Merck & Company have?
              Merck & Company has 2,532,806,400 shares outstanding.
                What happened to Merck & Company’s price movement after its last earnings report?
                Merck & Company reported an EPS of $2.07 in its last earnings report, beating expectations of $1.886. Following the earnings report the stock price went up 2.931%.
                  Which hedge fund is a major shareholder of Merck & Company?
                  Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
                    ---

                    Company Description

                    Merck & Company

                    Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
                    ---

                    MRK Company Deck

                    ---

                    MRK Earnings Call

                    Q1 2024
                    0:00 / 0:00
                    ---

                    MRK Sales Breakdown

                    45.91%45.91%22.09%5.64%5.60%20.75%
                    45.91% Oncology
                    22.09% Vaccines
                    5.64% Hospital Acute Care
                    5.60% Diabetes
                    20.75% Other
                    tipranks
                    ---

                    MRK Stock 12 Month Forecast

                    Average Price Target

                    $147.40
                    ▲(15.37% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"100":"$100","169":"$169","117.25":"$117.3","134.5":"$134.5","151.75":"$151.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$168.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$147.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$134.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[100,117.25,134.5,151.75,169],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.45,129.64615384615385,132.84230769230768,136.03846153846155,139.23461538461538,142.43076923076924,145.62692307692308,148.82307692307694,152.01923076923077,155.2153846153846,158.41153846153847,161.6076923076923,164.80384615384617,{"y":168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.45,128.06153846153848,129.67307692307693,131.2846153846154,132.89615384615385,134.5076923076923,136.11923076923077,137.73076923076923,139.34230769230768,140.95384615384617,142.56538461538463,144.1769230769231,145.78846153846155,{"y":147.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.45,127.03076923076924,127.61153846153846,128.1923076923077,128.77307692307693,129.35384615384615,129.9346153846154,130.51538461538462,131.09615384615384,131.6769230769231,132.2576923076923,132.83846153846153,133.41923076923078,{"y":134,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.17,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.27,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.99,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.87,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.38,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.46,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.79,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.87,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.41,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.23,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.75,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.89,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.45,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Pfizer
                    Bristol-Myers Squibb
                    Johnson & Johnson
                    Eli Lilly & Co

                    Best Analysts Covering MRK

                    1 Year
                    Geoff MeachamBank of America Securities
                    1 Year Success Rate
                    19/21 ratings generated profit
                    90%
                    1 Year Average Return
                    +15.90%
                    reiterated a buy rating 2 months ago
                    Copying Geoff Meacham's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +15.90% per trade.
                    Popular Stocks
                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis